BACKGROUND Non-cystic fibrosis (CF) bronchiectasis is characterised by chronic airway infection and neutrophilic inflammation, which we hypothesised would be associated with Th17 pathway activation. METHODS Th17 pathway cytokines were quantified in bronchoalveolar lavage fluid (BALF), and gene expression of IL-17A, IL-1β, IL-8 and IL-23 determined from endobronchial biopsies (EBx) in 41 stabl...

BACKGROUND A study was undertaken to investigate the incidence, diagnostic yield of non-invasive and bronchoscopic techniques, and risk factors of airway colonisation in patients with bronchiectasis in a stable clinical situation. METHODS A 2 year prospective study of 77 patients with bronchiectasis in a stable clinical condition was performed in an 800 bed tertiary university hospital. The i...

The majority of sufferers from bronchiectasis state that their symptoms began in childhood. There is good evidence for believing that the disease is usually of acquired origin, but in a few cases the presence of other developmental anomalies favours the view that there may also be a congenital factor. Sauerbruch (1934) considered bronchiectasis was due to mechanical crowding, particularly of th...

The rates of bronchiectasis for Indigenous children from remote Australian communities are unacceptably high, with one study showing 14.7/1000 Aboriginal children. Children with bronchiectasis need to be identified early for optimisation of medical treatment. Under-reporting of cough is common. Bronchiectasis should be suspected in children with recurrent bronchitis or pneumonia, and when, desp...

OBJECTIVE To describe clinical profile, etiology and outcome in children with non-cystic fibrosis bronchiectasis. METHODS A chart review of children diagnosed with non-cystic fibrosis bronchiectasis, attending pediatric chest clinic of tertiary care hospital. RESULTS The underlying cause was identified in 51 (63.8%) out of 80 children (mean age, 9.6 y). Common causes were post-infectious in...

This is the first guideline developed by the Saudi Thoracic Society for the diagnosis and management of noncystic fibrosis bronchiectasis. Local experts including pulmonologists, infectious disease specialists, thoracic surgeons, respiratory therapists, and others from adult and pediatric departments provided the best practice evidence recommendations based on the available international and lo...

Bronchiectasis is a chronic and progressive disease, which frequently is associated with a significant symptom burden and which may require intensive treatment. To date, epidemiological data on the prevalence of bronchiectasis in Europe are exceedingly scarce due to a great lack of research [1]. However, these data on disease burden are important in order to inform authorities and to allocate r...

HIV related bronchiectasis In their review of new developments in pulmonary diseases affecting HIV infected individuals (March 1995;50:294-302) Mitchell and Miller do not discuss bronchiectasis. They mention indolent bronchopulmonary Pseudomonas aeruginosa infection comparable to that seen in cystic fibrosis, but do not comment on bronchiectasis which is now well described in adults and childre...

BACKGROUND Non-cystic fibrosis bronchiectasis is characterized by the irreversible dilatation of the medium-sized bronchi as a result of airway injury from recurrent or chronic inflammation and lower respiratory tract infections. Bronchiectasis airways are commonly colonized with bacterial species. Infections of the airways play important role in bronchiectasis exacerbations. The non-specific p...

Bronchiectasis is permanently dilated airways caused by chronic bronchial inflammation secondary to inappropriate clearance of various micro-organisms and recurrent infections in the airways. At diagnosis, one should search for the underlying disease process, most of the time excluding cystic fibrosis (CF). However, in a substantial number of patients no cause is found. Next, patients need indi...